Protara Therapeutics, Inc. TARA
Regular-session close
After hours · Nov 18, 4:00 PM ET
- YTD
- -56.10%
- 1 year
- -65.33%
Discussion (63)
Bank of America Corp DE Buys 430,014 Shares of Protara Therapeutics, Inc. $TARA
Defense World StaffAug 29th, 2026
TARA — catalyst calendar
Period What to watch My expected stock impact
Aug–Sep 2026 ADVANCED-3 redesign / trial details 🟡 10–25% possible
Sep–Oct 2026 Further TARA-002 bladder-cancer updates 🟠 15–40% possible
Oct–Dec 2026 ADVANCED-2 completes BCG-unresponsive enrollment 🟠/🔴 Important
Q4 2026 THRIVE-3 interim Phase 3 results 🔴 Biggest near-term binary catalyst
Q4 2026 STARBORN-1 completes enrollment + additional LM data 🔴 Potentially major
Early 2027 More TARA-002 efficacy/durability data 🔴 Potentially major
2H 2027 TARA-002 BLA submission for lymphatic malformations 🔴🔴 Major
2027–28 Potential FDA approval/commercialization
Overreaction, it was never about a quarterly report, it’s about the soon to be approved cancer treatment drug that will make this company profitable and send the stock price up.
Scenario 1: TARA-002 becomes a best-in-class NMIBC therapy
This is the dream outcome.
Recent data showed:
72% complete response rate at any time
67% complete response at 6 months
55% complete response at 12 months in the BCG-naïve NMIBC cohort
Favorable safety profile with no Grade 3+ treatment-related adverse events reported in that update
If future registrational trials confirm strong efficacy, investors may value TARA as a future oncology commercial company rather than a speculative biotech.
Possible valuation:
Assume:
Market Cap Approximate Stock Price*
$500M ~$9
$1B ~$18
$2B ~$36
*Approximate based on ~56M shares outstanding; actual dilution could change this.
A $1B–$2B valuation is not impossible for a biotech with a successful cancer drug, but it requires major clinical and regulatory wins.
🚀 Catalysts That Could Send TARA Higher
- ADVANCED-3 registrational trial
This is probably the biggest catalyst.
The company has said it plans to initiate the ADVANCED-3 registrational trial in BCG-naïve NMIBC patients in the second half of 2026.
A strong trial design + FDA alignment could trigger institutional buying.
Potential impact: Very High ⭐⭐⭐⭐⭐ - FDA acceleration
TARA already received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations.
More FDA support for bladder cancer could dramatically change investor perception.
Potential impact: Very High ⭐⭐⭐⭐⭐ - Partnership / buyout speculation
Large oncology companies often acquire small biotech firms after promising Phase 2/3 data.
A partnership could:
validate TARA-002
bring upfront cash
reduce financing risk
Potential impact: Extremely High ⭐⭐⭐⭐⭐ - Short squeeze / momentum
Because TARA is a small biotech, positive news could create outsized moves if liquidity is limited.
This is a trading catalyst, not a fundamental one.
Potential impact: Medium-High ⭐⭐⭐⭐
I own it till it prints for as long as it takes $TARA
If things stay on course the upside will be huge $TARA
Crickets are good, as they say, buy the rumor, sell the news (when it blasts of beyond its target price).
$TARA Price Targets
Multiple analysts have issued price targets for $TARA recently. We have seen 5 analysts offer price targets for $TARA in the last 6 months, with a median target of $26.0.
Here are some recent targets:
Leland Gershell from Oppenheimer set a target price of $28.0 on 05/20/2026
Brian Cheng from JP Morgan set a target price of $26.0 on 05/14/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $27.0 on 04/29/2026
Kelsey Goodwin from Piper Sandler set a target price of $24.0 on 01/07/2026
$TARA could be a millionaire maker.
Just wait or buy more shares, need to be patient because the way I see it the big sharks are loading up.
